Geron Q1: RYTELO revenue $39.4M; demand flat; EU approval granted for LR-MDS

GERON CORP

2025-Q1 EPS reported -$0.03 revenue$39,603,000

RYTELO net product revenue $39.4M in Q1 2025; demand up only 1% vs prior 13 weeks due to inventory drawdown.
European Commission granted marketing authorization for RYTELO; launch in select EU countries planned for 2026.
Phase 3 IMpactMF trial for R/R myelofibrosis ~85% enrolled; interim OS analysis expected 2H 2026.
Net loss improved to $19.8M ($0.03/share) vs $55.4M ($0.09/share) in Q1 2024 on first product revenue.
FY2025 total operating expense guidance maintained at $270M-$285M; cash $457.5M as of March 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.